Skip to main content
NewslettersWatchlist

Cytomx Thera(CTMX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

Globe Newswire - Thu May 26, 2022

SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 (NCT05387265). CX-904 is a conditionally activated T-cell-engaging bispecific (TCB) designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

investor newsletter
A look at how people are using the best all-around investing product. Plus, top stock picks from our new Readers’ Portfolio
ETF or Exchange Traded Fund text on black block
market news
The close: Month-end repositioning spurs late-day stock rally
Trader Anthony Confusione works on the floor of the New York Stock Exchange, Thursday, May 30.
alternative investments
Why this money manager thinks investors should get off the sidelines but still be defensive
Illustration of Chris Kerlow for The Mover. June 23/24, 2023. Illustration by Joel Kimmel
globe advisor weekly newsletter
Canadian investors are ‘underserved’ in alternative investments and private capital
Investors want greater clarity from their advisors around what RI means and how it can fit their portfolios.
alternative investments
Why rising interest in traditional fixed income is not affecting alternatives
A man looks up as he leans a red ladder against a tall stack of coins that is topped with an interest rate symbol.
alternative investments
Fund houses buy up ‘alts’ specialists to move beyond equities and bonds
FILE PHOTO: Larry Fink, Chief Executive Officer of BlackRock, takes part in the Yahoo Finance All Markets Summit in New York, U.S., February 8, 2017. REUTERS/Lucas Jackson
opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza
alternative investments
Four ways to create more diversified and resilient portfolios
One of a set. Graphic Arrow on abstract background.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).